Keywords: ALK Abello, Torii Pharma, Mitizax, Hay fever, Asthma, Japanese trial program
ALK Abello partner Torii progresses Japanese development of Mitizax
Article | 01 August 2012
Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner, Japan-based Torii Pharma (TSE:4551), is advancing the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
